Wednesday, September 11, 2013
• Xenoport Inc., of Santa Clara, Calif., said it will advance XP23829, a fumaric acid ester compound that is a prodrug of monomethyl fumarate (MMF), in relapsing-remitting multiple sclerosis and/or psoriasis following positive preliminary results from two Phase I studies.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.